<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="BST-47-1757TB1" orientation="portrait" position="float">
 <label>Table 1.</label>
 <caption>
  <title>Summary of drugs with associated mitochondrial toxicity.</title>
 </caption>
 <table frame="hsides" rules="groups">
  <colgroup span="1">
   <col align="left" span="1"/>
   <col align="left" span="1"/>
   <col align="left" span="1"/>
   <col align="left" span="1"/>
   <col align="left" span="1"/>
  </colgroup>
  <thead>
   <tr>
    <th align="left" rowspan="1" colspan="1">Drug type</th>
    <th align="left" rowspan="1" colspan="1">Examples</th>
    <th align="left" rowspan="1" colspan="1">Mechanism</th>
    <th align="left" rowspan="1" colspan="1">Mitochondrial effects</th>
    <th align="left" rowspan="1" colspan="1">Clinical symptoms</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td rowspan="1" colspan="1">Antiviral-nuceloside reverse transcriptase inhibitor (NRTI)</td>
    <td rowspan="1" colspan="1">Zidovudine (AZT) (black box warning)
     <break/>Acyclovir (ACV)
     <break/>Ganciclovir (GCV)
     <break/>Zalcitabine (ddC)
    </td>
    <td rowspan="1" colspan="1">Analogues to endogenous dNTPs therefore inhibit mtDNA polymerase-γ and prevent chain elongation of nascent mtDNA chain [
     <xref rid="BST-47-1757C131" ref-type="bibr">131</xref>,
     <xref rid="BST-47-1757C132" ref-type="bibr">132</xref>]
    </td>
    <td rowspan="1" colspan="1">MtDNA depletion [
     <xref rid="BST-47-1757C26" ref-type="bibr">26</xref>,
     <xref rid="BST-47-1757C132" ref-type="bibr">132</xref>]
     <break/>Decreased synthesis of OXPHOS proteins, increased superoxide levels [
     <xref rid="BST-47-1757C133" ref-type="bibr">133</xref>]
     <break/>DNA breaks in mtDNA with ACV and GCV [
     <xref rid="BST-47-1757C134" ref-type="bibr">134</xref>]
     <break/>Abnormally structured mitochondria [
     <xref rid="BST-47-1757C135" ref-type="bibr">135</xref>,
     <xref rid="BST-47-1757C136" ref-type="bibr">136</xref>]
     <break/>Inhibition of cytochrome 
     <italic>c</italic> oxidase and citrate synthase [
     <xref rid="BST-47-1757C137" ref-type="bibr">137</xref>]
     <break/>Interference with the phosphoregulation of ETC subunits [
     <xref rid="BST-47-1757C26" ref-type="bibr">26</xref>]
    </td>
    <td rowspan="1" colspan="1">Lactic acidosis, altered lipid metabolism and altered carbohydrate metabolism [
     <xref rid="BST-47-1757C26" ref-type="bibr">26</xref>]
     <break/>Red-ragged fibers in muscle, myopathy [
     <xref rid="BST-47-1757C138" ref-type="bibr">138</xref>,
     <xref rid="BST-47-1757C139" ref-type="bibr">139</xref>]
     <break/>Neuropathy, liver steacidosis, pancreatitis [
     <xref rid="BST-47-1757C29" ref-type="bibr">29</xref>]
    </td>
   </tr>
   <tr>
    <td rowspan="1" colspan="1">Antiviral-protease inhibitor (PI)</td>
    <td rowspan="1" colspan="1">Saquinavir (black box warning)</td>
    <td rowspan="1" colspan="1">Inhibits cleavage of host cell polyprotiens into functional proteins [
     <xref rid="BST-47-1757C140" ref-type="bibr">140</xref>]
    </td>
    <td rowspan="1" colspan="1">Inability to assemble functional ETC [
     <xref rid="BST-47-1757C26" ref-type="bibr">26</xref>]
     <break/>Interference with lipid metabolism and retinoid signalling [
     <xref rid="BST-47-1757C141" ref-type="bibr">141</xref>]
    </td>
    <td rowspan="1" colspan="1">Lipodystrophy, hyperlipidaemia, insulin resistance [
     <xref rid="BST-47-1757C141" ref-type="bibr">141</xref>]
    </td>
   </tr>
   <tr>
    <td rowspan="1" colspan="1">Antibiotic</td>
    <td rowspan="1" colspan="1">Tetracycline</td>
    <td rowspan="1" colspan="1">Inhibition of protein synthesis</td>
    <td rowspan="1" colspan="1">Decreased mitochondrial membrane potential, down-regulation of ETC function and protein synthesis [
     <xref rid="BST-47-1757C67" ref-type="bibr">67</xref>,
     <xref rid="BST-47-1757C142" ref-type="bibr">142</xref>]
    </td>
    <td rowspan="1" colspan="1"/>
   </tr>
   <tr>
    <td rowspan="1" colspan="1"/>
    <td rowspan="1" colspan="1">Ciprofloxacin (black box warning)</td>
    <td rowspan="1" colspan="1">Inhibition of Top2 (topoisomerase) which prevents the relaxation of mtDNA for replication [
     <xref rid="BST-47-1757C143" ref-type="bibr">143</xref>]
    </td>
    <td rowspan="1" colspan="1">Inhibition of mtDNA replication, mtDNA depletion and dysregulation of ETC complexes [
     <xref rid="BST-47-1757C143" ref-type="bibr">143</xref>]
     <break/>dsDNA breaks [
     <xref rid="BST-47-1757C144" ref-type="bibr">144</xref>]
     <break/>Increased ROS levels and oxidative stress [
     <xref rid="BST-47-1757C145" ref-type="bibr">145</xref>]
     <break/>Respiration decreased 40% 
     <italic>in vitro</italic>, accompanied by reduced cytochrome 
     <italic>c</italic> oxidase (COX) activity and lactate accumulation [
     <xref rid="BST-47-1757C146" ref-type="bibr">146</xref>]
     <break/>Suppression of ETC complexes I and II [
     <xref rid="BST-47-1757C147" ref-type="bibr">147</xref>]
    </td>
    <td rowspan="1" colspan="1">Tendinopathies, neuropathies, myopathy and psychological symptoms [
     <xref rid="BST-47-1757C143" ref-type="bibr">143</xref>]
    </td>
   </tr>
   <tr>
    <td rowspan="1" colspan="1">Chemotherapy agent</td>
    <td rowspan="1" colspan="1">Cisplatin (black box warning)
     <break/>Cyclophosphamide
    </td>
    <td rowspan="1" colspan="1">Bind to the purine residues in the mtDNA of cells to cause damage in the DNA, inhibition of cell division and apoptotic cell death [
     <xref rid="BST-47-1757C148" ref-type="bibr">148</xref>,
     <xref rid="BST-47-1757C149" ref-type="bibr">149</xref>]
    </td>
    <td rowspan="1" colspan="1">Increased ROS production [
     <xref rid="BST-47-1757C36" ref-type="bibr">36</xref>,
     <xref rid="BST-47-1757C129" ref-type="bibr">129</xref>]
     <break/>mtDNA damage in lung and prostate cancer cells [
     <xref rid="BST-47-1757C150" ref-type="bibr">150</xref>]
     <break/>Decreased exercise capacity, decreased maximum mitochondrial ATP production [
     <xref rid="BST-47-1757C151" ref-type="bibr">151</xref>]
    </td>
    <td rowspan="1" colspan="1">Nephrotoxicity, ototoxicity [
     <xref rid="BST-47-1757C152" ref-type="bibr">152</xref>]
     <break/>Peripheral neuropathy [
     <xref rid="BST-47-1757C129" ref-type="bibr">129</xref>]
     <break/>Cardiac myopathy [
     <xref rid="BST-47-1757C36" ref-type="bibr">36</xref>]
     <break/>Hepatotoxicity [
     <xref rid="BST-47-1757C78" ref-type="bibr">78</xref>]
    </td>
   </tr>
   <tr>
    <td rowspan="1" colspan="1">Anti-psychotic</td>
    <td rowspan="1" colspan="1">Clozapine (black box warning)</td>
    <td rowspan="1" colspan="1">Binds serotonin and dopamine receptors with off-target effects on mitochondria [
     <xref rid="BST-47-1757C153" ref-type="bibr">153</xref>]
    </td>
    <td rowspan="1" colspan="1">Mitochondrial membrane depolarization, increased inflammatory response, mitochondrial swelling and changes in structure, all which resulted in ATP depletion [
     <xref rid="BST-47-1757C49" ref-type="bibr">49</xref>]
     <break/>Oxidation of mitochondrial proteins including malate dehydrogenase and pyruvate kinase [
     <xref rid="BST-47-1757C50" ref-type="bibr">50</xref>,
     <xref rid="BST-47-1757C154" ref-type="bibr">154</xref>]
    </td>
    <td rowspan="1" colspan="1">Obesity, metabolic disturbances and increased diabetes risk [
     <xref rid="BST-47-1757C50" ref-type="bibr">50</xref>,
     <xref rid="BST-47-1757C154" ref-type="bibr">154</xref>]
     <break/>Tardive dyskinesia [
     <xref rid="BST-47-1757C155" ref-type="bibr">155</xref>]
    </td>
   </tr>
   <tr>
    <td rowspan="1" colspan="1">Antiepileptic</td>
    <td rowspan="1" colspan="1">Sodium valporate (black box warning)</td>
    <td rowspan="1" colspan="1">Acts to increase the concentration of synaptic GABA with off-target effects on mitochondria [
     <xref rid="BST-47-1757C156" ref-type="bibr">156</xref>]
    </td>
    <td rowspan="1" colspan="1">Decreased membrane potential, ATP depletion, increased cell death and reduction in cell number [
     <xref rid="BST-47-1757C51" ref-type="bibr">51</xref>]
     <break/>Inhibition of the PDH complex [
     <xref rid="BST-47-1757C52" ref-type="bibr">52</xref>]
     <break/>Sequestration of free acetyls CoA [
     <xref rid="BST-47-1757C157" ref-type="bibr">157</xref>]
    </td>
    <td rowspan="1" colspan="1">Hepatotoxicity [
     <xref rid="BST-47-1757C51" ref-type="bibr">51</xref>,
     <xref rid="BST-47-1757C52" ref-type="bibr">52</xref>,
     <xref rid="BST-47-1757C157" ref-type="bibr">157</xref>]
     <break/>Metabolic disturbances [
     <xref rid="BST-47-1757C52" ref-type="bibr">52</xref>]
     <break/>Foetal anticonvulsant syndrome [
     <xref rid="BST-47-1757C53" ref-type="bibr">53</xref>]
    </td>
   </tr>
   <tr>
    <td rowspan="1" colspan="1">Antidepressant-selective serotonin reuptake inhibitor (SSRI)</td>
    <td rowspan="1" colspan="1">Sertraline
     <break/>Fluoxetine (black box warning)
    </td>
    <td rowspan="1" colspan="1">Acts to increase the concentration of serotonin by blocking reabsorption with off-target effects on mitochondria [
     <xref rid="BST-47-1757C158" ref-type="bibr">158</xref>]
    </td>
    <td rowspan="1" colspan="1">OXPHOS inhibited in isolated rat brain and liver mitochondria [
     <xref rid="BST-47-1757C159" ref-type="bibr">159</xref>,
     <xref rid="BST-47-1757C160" ref-type="bibr">160</xref>]
     <break/>Reduced mitochondrial biogenesis [
     <xref rid="BST-47-1757C161" ref-type="bibr">161</xref>]
     <break/>Ion compartmentalization [
     <xref rid="BST-47-1757C162" ref-type="bibr">162</xref>]
     <break/>Change in morphology to more rounded and shrivelled, indicative of increased caspase 3 activity [
     <xref rid="BST-47-1757C163" ref-type="bibr">163</xref>]
     <break/>Decreased respiratory activity [
     <xref rid="BST-47-1757C164" ref-type="bibr">164</xref>]
     <break/>Inhibition of complexes I, III and IV in the ETC [
     <xref rid="BST-47-1757C163" ref-type="bibr">163</xref>]
     <break/>Down-regulation of ETC proteins [
     <xref rid="BST-47-1757C165" ref-type="bibr">165</xref>]
    </td>
    <td rowspan="1" colspan="1">Hyponatremia, weight gain [
     <xref rid="BST-47-1757C166" ref-type="bibr">166</xref>]
    </td>
   </tr>
  </tbody>
 </table>
</table-wrap>
